Endometrial (Uterine) cancer trials

AI-generated summary

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors is being studied. Conditions: Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult +25 • Eligibility: Inclusion Criteria: \- Must have a pathologically confirmed advanced and unresectable or metastatic solid tumor listed below with documented disease progression on last standard treatment. Part 1 only:…. Goal: The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D). Phase/Status/Sponsor: Unknown phase; RECRUITING; NiKang Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests maintenance therapy with letrozole and abemaciclib for adults with ER-positive, mismatch repair–proficient, TP53 wild-type endometrial cancer that has advanced or recurred after initial carboplatin/paclitaxel chemotherapy (with or without anti-PD-(L)1 therapy). - It is a single-arm phase 2 trial at Dana-Farber Cancer Institute, enrolling about 32 participants, with treatment for up to 2 years and follow-up for 3 years after treatment ends. - Eligible participants must have ER-positive, MMR-proficient, TP53 wild-type disease and have completed a defined amount of prior chemotherapy; key exclusions include prior CDK4/6 inhibitor treatment, active brain metastases, pregnancy, and certain drug interactions with CYP3A4. - The study will monitor safety and effectiveness using imaging and laboratory tests to learn whether this drug combination helps control the cancer in this specific group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) is being studied. Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer +27 • Eligibility: Inclusion Criteria: * At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval. * Locally advanced or metastatic solid malignancy…. Goal: The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; PMV Pharmaceuticals, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests Puxi-Sam (puxitatug samrotecan) as a single-drug treatment versus doctors’ choice of chemotherapy (doxorubicin or paclitaxel) for people with B7-H4–selected advanced or metastatic endometrial cancer that has progressed after platinum-based therapy and anti-PD-1/PD-L1 therapy. It is a phase III, randomized, multicenter global study enrolling about 700 participants in a 1:1 ratio. The study aims to find out if Puxi-Sam can help people live longer without their cancer getting worse or live longer overall, and how it affects safety and quality of life. Key exclusions include uterine sarcomas or neuroendocrine carcinoma, prior TOP1 inhibitor therapy or Puxi-Sam/B7-H4 therapies, active or a history of ILD/pneumonitis or autoimmune disorders, and more than 12 months since completing platinum therapy in the curative setting without additional platinum.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors is being studied. Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer +6 • Eligibility: Inclusion Criteria: 1. Adult participants must be 18 years of age or older 2. Advanced or metastatic solid tumors excluding primary central nervous system (CNS) tumors 3. For…. Goal: The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; IDEAYA Biosciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors is being studied. Conditions: Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer • Eligibility: Core Inclusion Criteria: * Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. * Provision…. Goal: This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DESTINY-PANTUMOUR04 is being studied. Conditions: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer +24 • Eligibility: Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic…. Goal: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers is being studied. Conditions: Cancer • Eligibility: Abbreviated Inclusion Criteria: 1. Subject with histological diagnosis of advanced/metastatic cancer \[currently enrolling in CRC only\] 2. Age 18 years or older, is willing and able to provide…. Goal: TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tizona Therapeutics, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome is being studied. Conditions: Endometrial Cancer, Lynch Syndrome, Screening +1 • Eligibility: Pre-pilot study Inclusion criteria: * Individuals over the age of 18 * Menstruating Exclusion criteria: * Levonorgestrel IUD in situ or removed within the last 30 days prior…. Goal: Study Goal: This pilot study wants to find out if using a menstrual cup can be a good, non-invasive way to collect samples from the lining of the uterus (called the endometrium) to help screen for endometrial cancer. This is especially important for women who have a higher chance of getting this cancer, such as those with a genetic condition called Lynch syndrome. Phase/Status/Sponsor: Unknown phase; RECRUITING; Jessica D. St. Laurent, MD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests GV20-0251 to see if it is safe in adults with advanced or refractory solid tumors. It is a single-center, single-arm early-stage trial at West China Hospital. It uses a 3+3 dose-escalation design, starting with 10 mg/kg and 20 mg/kg given every three weeks, to find a tolerable dose and watch for dose-limiting toxicities. The trial covers multiple solid tumor types to learn about safety and dosing across indications. Key exclusions include active infections, certain heart problems or QT prolongation, autoimmune disease needing immunosuppressive therapy, HIV/HBV/HCV infections, pregnancy, and recent major surgery.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Johns Hopkins trial is currently recruiting and tests using MRI to guide gynecologic brachytherapy, comparing it with CT planning to see if MRI can better show the tumor and protect nearby healthy tissues. It is for adults with gynecologic cancers (cervix, uterus, vagina, vulva, or urethra) who are eligible for internal brachytherapy, including people who have had prior radiation or chemotherapy. Researchers want to learn if MRI-guided planning lowers the radiation dose to nearby organs and to find safe dose levels that minimize side effects, checking outcomes at 6 months, 1 year, and 2 years after treatment. Key exclusions include uncontrolled illness, very low white blood cell count (ANC < 500), or metal in the head or eyes; participants must be able to give informed consent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether organoids—miniature lab-grown versions of endometrial tumors—can be generated from tumor tissue collected during surgery, and it looks at how transporting samples affects tissue viability and the success of organoid culture. It is for adults with endometrial cancer (including endometrioid type and any stage) who are candidates for surgery or hysterectomy. The study will also use blood and tissue to perform genomic analyses (RNA sequencing and whole-exome sequencing) and to test organoid responses to immunotherapy in coculture experiments. It is exploratory and will not change standard diagnostic or treatment plans; exclusions include uncontrolled comorbidities, pyometra, synchronous tumors, prior neoadjuvant therapy, or prior pelvic radiation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons is being studied. Conditions: Endometrial Cancer, Endometrial Cancer Precursors, Ovarian Cancer +1 • Eligibility: INCLUSION CRITERIA: * Individuals born with female sex organs (uterus, ovaries, including cis-gender female and transmasculine individuals, hereafter referred to as "women") scheduled for hysterectomy or bilateral salpingo-oopherectomy…. Goal: BACKGROUND: Endometrial cancer is a common and deadly cancer for women. It is getting more common and deadly because risk factors like age and obesity are increasing. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Alabama at Birmingham.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests LY4066434, a pan-KRAS inhibitor, in people with KRAS-mutant solid tumors. - It includes patients whose tumors have specific KRAS mutations (G12C, G12D, G12V, G12A, G12S, or G13D) and who have locally advanced, unresectable, or metastatic cancer with measurable disease. - The trial will evaluate LY4066434 alone or with other treatments to see if it is safe and tolerable, using two parts: monotherapy dose escalation and dose optimization, over up to about 5 years. - Key exclusions include active CNS metastases, significant cardiovascular disease, active hepatitis B or C or untreated HIV, other active cancers, and uncontrolled infections.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether multiparametric ultrasound imaging (mpUS) can evaluate vaginal tissue before and after IVRT in people with endometrial cancer. It is for adults with primary endometrial carcinoma who have had surgery to remove the uterus, ovaries, and lymph nodes, have no residual disease, are stage I–II, and can start radiotherapy within 12 weeks of surgery. The researchers want to learn how well mpUS works for this purpose and whether participants can tolerate all mpUS imaging. Exclusion criteria include receiving chemotherapy or hormonal therapy, prior pelvic radiotherapy, active genitourinary infection requiring antibiotics, inflammatory bowel disease, or other conditions that would make enrollment inappropriate.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests zanzalintinib in combination with paclitaxel to find the best dose for the next phase in people with recurrent high-grade uterine cancer. It also aims to assess safety and tolerability and to learn how often tumors respond to the treatment. Eligible participants are adults with recurrent high-grade uterine cancer (including endometrioid, serous, mixed high-grade, or uterine carcinosarcoma) who progressed on or could not tolerate platinum therapy, with 1–2 prior cancer treatments and measurable disease. Key exclusions include prior exposure to zanzalintinib, known brain metastases unless adequately treated and stable, recent use of certain therapies, QT prolongation, pregnancy, and other conditions that could make participation unsafe.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests whether using the Headspace mindfulness app before cancer treatment helps people with endometrial cancer needing surgery or cervical cancer treated with chemoradiation. Participants are randomly assigned to use the Headspace app before treatment or not. Eligible participants have a new cancer diagnosis and a smartphone; those who do not speak English, do not have a smartphone, or are already using Headspace are excluded. The goal is to learn whether mindfulness practice before treatment can reduce stress and anxiety and improve the treatment experience.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Beta-only IL-2 ImmunoTherapY Study is being studied. Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma +34 • Eligibility: Key Inclusion Criteria: 1. Aged at least 18 years (inclusive at the time of informed consent). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.…. Goal: This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Medicenna Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a prospective cohort study to establish a uterine cavity diseases research platform and collect comprehensive clinical data from women with intrauterine diseases. - It will enroll women aged 18-80 who need hysteroscopy or diagnostic curettage for conditions such as endometrial hyperplasia, endometrial polyps, submucosal fibroids, adenomyosis, or endometrial malignancies. - After hysteroscopic surgery, participants will be followed for one year to observe disease progression and treatment outcomes. - The study aims to learn about the pathogenesis, risk factors, and optimized treatment strategies for uterine cavity diseases. - Exclusion criteria include concurrent participation in other drug trials, contraindications to hysteroscopy/curettage, or inability/unwillingness to consent or adhere to the protocol.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether a program of physical activity plus a healthy diet can improve muscle health and metabolism in women with endometrial cancer who are planned for staging surgery. - It compares women who follow the exercise and diet plan to a group that does not exercise, measuring muscle size, strength, and function, along with blood markers related to muscle health, inflammation, and glucose/lipid metabolism. - The researchers want to see if these changes are linked to better surgical recovery and overall health, and whether blood tests could help monitor muscle health. - Eligible participants are women 18–65 with endometrioid endometrial cancer who are candidates for staging surgery and able to attend sessions; key exclusions include advanced disease, another cancer, uncontrolled hypertension, kidney dysfunction, and other conditions that make exercise unsafe.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests Tulmimetostat (DZR123/CPI-0209) as a single-drug therapy for advanced solid tumors and lymphomas, and also in combination with enzalutamide for metastatic castration-resistant prostate cancer (mCRPC) in a later cohort. It starts with Phase 1 to find the safe dose (MTD/RP2D) and then moves to Phase 2 to assess safety, tolerability, and early anti-tumor activity across several disease-specific groups (including ARID1A-mutant endometrial/urothelial cancers and M7) and a combination cohort (M8). Participants are adults with various advanced cancers, with certain molecular subtypes and measurable disease, all with good performance status and organ function. Key exclusions include active brain metastases, significant cardiovascular disease, recent major surgery, uncontrolled infections, and prior EZH2 inhibitors; for the M8 cohort, prior enzalutamide or other AR pathway inhibitors may also exclude eligibility.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

NYSCF Scientific Discovery Biobank is being studied. Conditions: ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease +26 • Eligibility: Inclusion Criteria: * Age 30 days or older. * Diagnosis and/or medical history of a condition, disease, genetic background, or trait of interest or healthy control. * Adults…. Goal: The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time. Phase/Status/Sponsor: Unknown phase; RECRUITING; New York Stem Cell Foundation Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial, being conducted at Regina Elena Cancer Institute, tests an AI and machine-learning based risk prediction model called the MOMIMIC score to improve preoperative management of endometrial cancer by combining multi-omics data and immune patterns with hysteroscopic and radiogenomic information. It includes adults over 18 with endometrial hyperplasia, endometrioid adenocarcinoma, or healthy endometrium in patients undergoing hysterectomy for benign disease. The aim is to learn whether the MOMIMIC score can predict progression from precancerous lesions to cancer, overall prognosis, and risk of recurrence, to guide treatment decisions. The study will use AI applied to hysteroscopic video and to robotic/laparoscopic video to help surgeons decide on procedures and may support fertility-sparing options for young patients with low-risk profiles. Exclusion criteria include uncontrolled comorbidities, endometrial infection, synchronous cancer, prior pelvic radiotherapy, neoadjuvant treatment, and hormone therapies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests KD01, a recombinant oncolytic adenovirus, to evaluate its safety, tolerability, and anti-tumor activity in gynecologic cancers. - It has Phase I for patients who have failed standard therapy, and Phase II with two groups: cervical cancer patients who want to preserve fertility and endometrial cancer patients with specific features. - The researchers aim to learn how KD01 works in the immune system and its ability to kill tumor cells, while also assessing overall safety. - Key exclusions include serious cardiovascular disease, active infections, autoimmune disorders, HIV/HBV/HCV infection, prior oncolytic therapy, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer is being studied. Conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer • Eligibility: Inclusion Criteria: 1. Volunteer to participate in the study, be able to understand the requirements of a clinical study, and willingness to sign a written informed consent form.…. Goal: The goal of this clinical trial is to learn if the investigational drug BL0175 works to treat adult postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative locally advanced or metastatic breast cancer, ovarian cancer and endometrial cancer. It will also learn about the safety of BL0175. Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Best-Link Bioscience, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests a shorter pelvic radiation course (hypofractionation) for women with non-metastatic endometrial cancer. Researchers want to find the safest and most tolerable dose for this shortened treatment. Each daily dose is slightly higher so the total radiation amount is similar to standard treatment. The study is sponsored by the University of Chicago and is currently recruiting; eligible participants are adults with non-metastatic uterine cancer who have had definitive surgery (hysterectomy) and will receive whole-pelvic radiotherapy without concurrent chemotherapy. Exclusions include distant metastases, gross residual disease after surgery, prior pelvic radiation, planned para-aortic nodal irradiation, and certain bowel or ongoing chemotherapy issues.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1 Study of LNCB74 in Advanced Solid Tumors is being studied. Conditions: Ovarian Cancer, Breast Cancer, Endometrial Cancer +3 • Eligibility: Inclusion Criteria: 1. The participant provides written informed consent 2. ≥ 18 years of age on day of signing informed consent. 3. Participant with histologically or cytologically confirmed…. Goal: This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; NextCure, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MT-4561 in Patients With Various Advanced Solid Tumors is being studied. Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer +13 • Eligibility: Main Inclusion Criteria: Patients who have failed at least 1 prior therapy and, who have no standard treatment options demonstrated to provide clinical benefit or who are intolerable…. Goal: This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tanabe Pharma America, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features (RAINBO) is an international program testing four different adjuvant treatment approaches for endometrial cancer based on the tumor’s molecular features. In p53-abnormal tumors, the trial tests adjuvant chemoradiation followed by one year of olaparib; mismatch repair–deficient tumors study radiotherapy with durvalumab for one year (vs radiotherapy with/without chemotherapy); NSMP tumors compare radiotherapy followed by progestogens to chemoradiation; POLE-mutant tumors test de-escalation, with no adjuvant therapy for some stages or radiotherapy only for others. The program aims to compare molecular-feature–guided therapy to standard adjuvant therapy to learn about effectiveness, toxicity, quality of life, and cost. Eligibility requires confirmed endometrial cancer with full molecular classification, completed surgery with no residual disease and no distant metastases, and consent; major exclusions include prior pelvic radiation and history of another primary cancer in the past five years, with additional arm-specific exclusions such as POLE mutations, prior PD-1 inhibitors, or other protocol-specific rules.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss is being studied. Conditions: Gynaecological Cancers • Eligibility: Inclusion Criteria: 1. Histologically confirmed progressive or recurrent gynaecological carcinomas of the following histological subtypes: Cohorts 1A, 1B, 2 and 3: * Clear cell (Ovarian, endometrial or endometriosis-related,…. Goal: ATARI trial tests the ATR inhibitor drug ceralasertib (AZD6738) alone and in combination with either a PARP inhibitor drug called olaparib, or an anti-PD-L1 immunotherapy called durvalumab (MEDI4736) in patients with relapsed gynaecological cancers to assess the response in groups of patients selected based on their cancer cell subtype and the presence of an abnormality in the ARID1A gene. Phase/Status/Sponsor: Unknown phase; RECRUITING; Institute of Cancer Research, United Kingdom.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors is being studied. Conditions: Stage IV Ovarian Cancer, Testis Cancer, Refractory, Endometrial Cancer Recurrent +1 • Eligibility: Inclusion Criteria: 1. patients with advanced ovarian cancer or other cancers with expression of claudin6. 2. Life expectancy \>12 weeks 3. Adequate heart,lung,liver,kidney function 4. Available autologous transduced…. Goal: This study is an open, exploratory clinical study to evaluate the safety and preliminary efficacy of Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells in patients with Claudin6, GPC3, Mesothelin, or AXL-positive advanced solid tumors (ovarian cancer and others) Phase/Status/Sponsor: Unknown phase; RECRUITING; Second Affiliated Hospital of Guangzhou Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The EUGENIE trial is a multicentre interventional study that is currently recruiting, testing a new approach that combines genomic profiling with surgical assessment to improve endometrial cancer staging and treatment decisions. Researchers want to see how the four molecular subgroups (POLE, MMRd, p53abn, NSMP) relate to disease stage and prognosis, and whether molecular classification can help guide how extensive the surgical staging should be. The trial is for adult women (age 18 and older) who are newly diagnosed with endometrial cancer, at any stage and with any histology. Exclusion criteria include prior pelvic or para-aortic lymph node dissection or sampling, prior pelvic radiotherapy or neoadjuvant chemotherapy, and any condition or prior treatment that could jeopardize safety or the study’s integrity.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies is being studied. Conditions: Gastric Cancer, Bladder Cancer, Squamous Non-small Cell Lung Cancer +4 • Eligibility: Inclusion Criteria: * Patient or legal guardian, if permitted by local regulatory authorities, provides informed consent to participate in the study must be performed before any procedure's protocol…. Goal: The purpose of the study is to determine to evaluate safety and tolerability of CPL304110 when administered once daily to adults with advanced solid malignancies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Celon Pharma SA.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Assessing Uterine Cancer Risk in Lynch Syndrome Carriers Using Vaginal Self-sampling and a Health Questionnaire is being studied. Conditions: Endometrial Cancer, Lynch Syndrome • Eligibility: Inclusion Criteria: * Diagnosed with Lynch syndrome (confirmed by genetic testing). * Have an intact uterus. * Age 30 years or older. Exclusion Criteria: * History of endometrial…. Goal: The goal of this study is to find out if self-collected vaginal swabs can be used to detect early signs of uterine cancer or related conditions in people with Lynch syndrome (LS) who still have their uterus. The study also tests if people with LS are willing and able to collect these samples themselves and whether they find the process acceptable. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of British Columbia.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests POLE mutation status in high-risk recurrent endometrial cancer. It will analyze women with high-risk recurrent endometrial cancer treated at a tertiary referral center and perform POLE mutation analysis. It aims to learn how common POLE mutations are and what impact they have on real-world outcomes using survival analysis. Eligible participants are women with high-risk recurrent endometrial cancer; there are no exclusion criteria. The trial is currently Recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Development and Management of Registry in Patients With Gynecologic Cancer in Korea is being studied. Conditions: Cervical Cancer, Endometrial Cancer, Ovarian Cancer +2 • Eligibility: Inclusion Criteria: * Female patients 18 years or older * Written informed consent (prospective cohort) * Confirmed diagnosis of cervical cancer, endometrial cancer or ovarian cancer Exclusion Criteria:…. Goal: The goal of this observational study is to identify and analyze the characteristics, treatment trends, prognostic factors and survival prognosis of Korean gynecologic cancer patients. Ultimately, the final goal is to contribute to the development of safe surgical methods and treatment for gynecologic cancer to improve survival rates. Phase/Status/Sponsor: Unknown phase; RECRUITING; Asan Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors is being studied. Conditions: Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor +2 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 years. For subjects with GCTs, age ≥15 years * CLDN6+ tumor * Histological or cytological documentation of locally advanced, recurrent, or…. Goal: The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes. Phase/Status/Sponsor: Unknown phase; RECRUITING; Xencor, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests a new PET/CT tracer, 68GaNOTA-Anti-HER2 VHH1, to image HER2 expression in tumors. It is for adults with locally advanced or metastatic breast cancer (cohort 1), other HER2-expressing cancers (cohort 2), and HER2-positive breast cancer planned for neoadjuvant treatment (cohort 3), and the study is currently recruiting. The goal is to learn how repeatable the HER2 imaging is and how tracer uptake matches biopsy results when available, plus whether the tracer adds value in the neoadjuvant setting. Key exclusions include pregnancy or breastfeeding, serious infections or other life-threatening illnesses, inability to consent or cooperate, and, for cohorts 1 and 3, prior participation in this study.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase III, open-label, multicentre, randomized trial comparing dostarlimab with carboplatin-paclitaxel as first-line treatment for adults with MMR-deficient (MMRd/MSI-H) endometrial cancer that is recurrent or advanced. It is for women aged 18 and older with MMRd/MSI-H endometrial cancer who have measurable disease and ECOG 0-1. Randomization is 1:1 and stratified by prior adjuvant chemotherapy, prior pelvic radiotherapy, and whether the disease is newly diagnosed advanced/metastatic or relapse. Exclusion criteria include prior anti-PD-1/PD-L1 therapy, active brain metastases, certain active infections or autoimmune disease, and recent systemic anticancer therapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology is being studied. Conditions: Gynecologic Disease, Gynecologic Cancer, Endometriosis +5 • Eligibility: Inclusion Criteria: 1. Subject of legal age (according to local legislation) and at least 18 years old 2. Subject (and if applicable her legal representative) having dated and…. Goal: GynRAN is an international, multicentre, transversal, diagnostic and non-interventional study carried out in gynecology-obstetrics/gynecological oncology departments that aims to identify a diagnostic signature for gynecological pathologies by analyzing of coding and non-coding RNA contained in patients saliva. The study population consists of patients with clinically symptomatic females with one or more of the gynecological pathologies (endometriosis, adenomyosis, ovarian cysts, fibroids, ovarian/cervical/uterine cancer) and asymptomatic females. Phase/Status/Sponsor: Unknown phase; RECRUITING; ZIWIG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN) is being studied. Conditions: Solid Tumor, Advanced Solid Tumor, Locally Advanced Solid Tumor +11 • Eligibility: Inclusion Criteria: Patients eligible for inclusion in this study have to meet all of the following criteria: * Patients, 18 years of age or older * Competent and…. Goal: The implementation of liquid biopsy in clinical practice has been favored by the rapid development of genome sequencing techniques designed to analyze mutations in ctDNA. Among these, the Next generation sequencing (NGS) is a technique that consists in sequencing several genomes in a short time span, collecting information about a wider range of genomic alterations, using small quantities of genetic material. Phase/Status/Sponsor: Unknown phase; RECRUITING; Centro di Riferimento Oncologico - Aviano.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Lipid Mediators & Cancer: Montelukast, SPM, and Almonds is being studied. Conditions: Colorectal Cancer, Sarcoma, Brain Tumors +2 • Eligibility: Inclusion Criteria: 1. Newly diagnosed individuals with stages I-IV colorectal or ovarian cancer, grade 1 and 2 endometrial cancer, as well as those with brain tumors or sarcoma.…. Goal: The purpose of this study is to create a prospective investigation to examine the effects of montelukast, almonds/almond oil, and specialized pro-resolving mediators (SPMs) on lipid profiles and tumor-associated macrophages (TAMs) in cancer patients (colorectal cancer, sarcoma, brain tumors, endometrial cancer, and ovarian cancer). The focus will be on assessing changes in lipid mediator concentrations, TAM reprogramming, and immune cell function in treated versus untreated patients. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; University of South Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors is being studied. Conditions: Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer +5 • Eligibility: Inclusion Criteria: * diagnosed with any of the following cancers \[Stage I-III\]: breast, prostate, urinary bladder, and endometrial in the past 6 months; * being treated for cancer…. Goal: The purpose of this randomized clinical trial is to learn if 'complex' cancer patients who receive care guided by a health system intervention, Primary Care Connect (PC2) have their risks of cardiovascular disease (CVD) managed better than those who receive usual care. This study focuses on "complex" cancer survivors who have higher CVD risk when diagnosed with cancer because they also have had a diagnosis of 1 or more chronic conditions (e.g., hypertension, diabetes, and/or hyperlipidemia) requiring medication management. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Rutgers, The State University of New Jersey.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer is being studied. Conditions: Endometrial Cancer, Endometrioid Carcinoma, Mismatch Repair Deficiency • Eligibility: Inclusion Criteria: * Be between the ages of 18-45 years old; * Stage IA (FIGO 2009) ; * Confirmed diagnosis of endometrial adenocarcinoma G1-G2 based upon D\&C or…. Goal: The objective of this study was to investigate the feasibility of a PD-1 inhibitor in combination with progesterone as a means of preserving fertility in patients with early-stage mismatch repair-deficient (MMRd) endometrial cancer who wish to preserve fertility. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Peking University People's Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

GYNORYLAQ-VLINIVAL is an early-phase, non-randomized, single-arm trial enrolling by invitation to test a personalized neoantigen vaccine for people with high-risk or recurrent endometrial cancer. The vaccine, called GYNORYLAQ-TM, is selected for each patient by the GYNORYLAQ-EC platform and given with individualized background cancer therapies chosen by the treating oncologist; the vaccine itself is investigational. The study aims to evaluate safety and tolerability and to assess the feasibility of manufacturing GMP-grade, patient-specific vaccine panels. Secondary goals include measuring vaccine-induced T-cell immune responses and exploring how the platform’s quantum/physics scores relate to clinical and immunologic outcomes. Eligibility requires confirmed high-risk or recurrent endometrial cancer with measurable disease; key exclusions include active uncontrolled infection, autoimmune disease requiring systemic immunosuppression, untreated CNS metastases, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies is being studied. Conditions: Ovarian Cancer, Breast Cancer, Pancreatic Cancer +10 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 at the time of screening * Histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and…. Goal: This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health is being studied. Conditions: Breast Cancer, Colorectal Cancer, Endometrial Cancer +6 • Eligibility: Inclusion Criteria: * Age 50 years or older * Resident of the continental United States * Diagnosed with multiple myeloma, non-Hodgkin lymphoma, or localized kidney or ovarian cancer;…. Goal: This research study will test the efficacy of interactive, web-based interventions that improve diet, physical activity and weight management changes among early stage survivors of breast, prostate, colorectal, endometrial, renal, thyroid, and ovarian cancers, as well as multiple myeloma and non-Hodgkin Lymphoma. Overarching outcomes also include physical function and performance, muscle mass, quality of life, and health utilities. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Alabama at Birmingham.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The ANTARES study is testing whether nivolumab, a PD-1 blocker, can work in people with advanced or metastatic rare tumors that express PD-L1 (CPS ≥ 10), regardless of tumor type. It is a phase II basket trial, enrolling adults whose cancers have higher PD-L1 expression after standard treatments have failed. Treatment can last up to 12 months, and researchers will look at objective responses, progression-free survival, and biomarkers like PD-L1, ctDNA, and microvesicles. Exclusions include prior immunotherapy, pregnancy or breastfeeding, active infection, autoimmune disease (with limited exceptions), and uncontrolled CNS metastases, among other health criteria.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Genetic Testing in African Americans is being studied. Conditions: Ovarian Cancer, Endometrial Cancer, Peritoneal Cancer • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years of age. 2. New diagnosis of ovarian, endometrial, fallopian, or primary peritoneal carcinoma. 3. Diagnostic procedure performed at AU Health Medical…. Goal: This is a pilot/feasibility study to conduct genetic testing using tumor/blood samples of African American and Caucasian patients with ovarian and endometrial cancer following surgery at AU Health Medical Center. The aim of the pilot/feasibility study is to sequence a panel of cancer genes on paired tumor/blood (germline) samples of patients with ovarian and endometrial tumors at a two-week time point following surgery at AU Medical Center. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Augusta University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests botensilimab, an Fc-engineered anti-CTLA-4 monoclonal antibody, alone and in combination with balstilimab (anti-PD-1) in advanced solid tumors to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, and to identify the maximum tolerated dose and the recommended Phase 2 dose. - It is for adults with refractory, advanced cancers and will enroll up to about 550 evaluable participants across multiple cancer types, including NSCLC, melanoma, hepatocellular cancer, and others. - The trial uses a 3+3 dose-escalation design to determine dosing and will also explore safety, PK/PD, and potential clinical activity at doses deemed potentially effective. - Key exclusions include active brain metastases unless treated with specific criteria, active autoimmune disease requiring systemic therapy, active infection, pregnancy or breastfeeding, and certain recent or concurrent cancer therapies (prior CTLA-4 therapy may be allowed in some indications with sponsor agreement).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a randomized trial testing cabozantinib s-malate plus nivolumab versus nivolumab alone in adults with advanced, recurrent, or metastatic endometrial cancer that has progressed after platinum-based therapy. - The study aims to learn whether the combination can improve progression-free survival and overall response rate, and to look at overall survival and safety. - It will also examine biomarkers such as PD-L1, T-cell infiltrates, and MSI/MMR status to see how they relate to outcomes. - Key exclusions include untreated or uncontrolled brain metastases (with some allowed if previously treated and controlled), prior cabozantinib, active infections or significant cardiovascular issues, pregnancy or breastfeeding, and the requirement for a baseline biopsy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial is testing the safety of dostarlimab in Indian adults with recurrent or advanced endometrial cancer that has progressed after platinum-based therapy. It aims to learn how safe dostarlimab is for people whose tumors are dMMR/MSI-H and who are eligible to receive the drug. Participants must be 18 or older, able to give consent, have a negative pregnancy test, and use contraception if needed; several health-related exclusions apply. The study is not yet recruiting, and GlaxoSmithKline is the sponsor.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is an observational study funded by Cycle Therapeutics Ltd that will collect menstrual fluid and uterine tissue and relate these samples to health outcomes to look for disease signatures. It aims to identify early diagnostic markers, improve disease classification, and help create lab models to discover new treatments for endometriosis and related conditions. The study is for women aged 16 and older, with most samples from those who are menstruating or undergoing biopsies; women with suspected endometriosis are encouraged to participate, as are healthy donors to help establish a baseline. People who are not menstruating are excluded, and the study is not yet recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests dostarlimab with carboplatin and paclitaxel, followed by dostarlimab alone, in Japanese participants with primary advanced or recurrent endometrial cancer. - It aims to learn how well this treatment works and how safe it is for people with endometrial cancer, including tumors that are dMMR/MSI-H or MMRp/MSS. - Eligible participants have Stage III or IV disease or first recurrence with limited curability and at least one measurable lesion, plus good performance status. - Key exclusions include having another active cancer or recent cancer treatment, uncontrolled liver or lung disease, uncontrolled brain metastases, immune system problems, prior immune checkpoint inhibitor therapy, pregnancy, HIV or hepatitis B/C infection, recent anticancer therapy, or a contraindication to carboplatin or paclitaxel.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Asian Multicenter Prospective Study of ctDNA Sequencing is being studied. Conditions: Cervical Cancer, Ovarian Clear Cell Carcinoma, Nasopharyngeal Carcinoma +3 • Eligibility: Inclusion Criteria: 1. Age of 18 years or older at registration. 2. Diagnosis of cancer which is targeted by each cohort. 3. Metastatic and/or recurrent disease. Exclusion Criteria:…. Goal: This study is a genetic analysis of aberrations in circulating tumor DNA (ctDNA) in patients in Asian countries. This study protocol is divided into parts describing several subanalyses that differ in terms of cancer types, analytical methods, participating countries, and participating institutions. Phase/Status/Sponsor: Unknown phase; UNKNOWN; National Cancer Center, Japan.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? is being studied. Conditions: Carcinosarcoma, Endometrial Neoplasms • Eligibility: Inclusion Criteria: 1. Histologically confirmed advanced or recurrent endometrial carcinoma or carcinosarcoma. 2. Aged \>16 years. 3. All participants must have received at least one prior line of…. Goal: The COPELIA trial is evaluating two new tablet medications in endometrial cancer for the first time. It will include 129 women aged 16 years or older with advanced endometrial cancer whose cancer has worsened after their initial chemotherapy treatment. Phase/Status/Sponsor: Unknown phase; UNKNOWN; University of Manchester.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer is being studied. Conditions: Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer +1 • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed previously untreated ovarian cancer, fallopian tube carcinoma, papillary serous cancer of the uterus, or primary peritoneal carcinoma * Suboptimally debulked stage III or…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Herbert Irving Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers is being studied. Conditions: Breast Neoplasms, Endometrial Neoplasms, Cervix Neoplasms +1 • Eligibility: Inclusion Criteria: * Resistant breast, endometrial, cervix, or ovarian cancer * No active metastasis to the brain * No more than 8 previous regimes of Doxil * Successful…. Goal: Thermal therapy (hyperthermia of heat) can increase the effect of chemotherapy treatments. By itself, thermal therapy can also kill cancer cells. Phase/Status/Sponsor: Unknown phase; UNKNOWN; The University of Texas Health Science Center, Houston.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The PIONEER Initiative is testing a system to provide functional precision medicine testing on a patient’s tumor tissue, which can include organoid drug screening and genomic profiling to help guide therapy decisions. It is for all cancer patients and for people at risk of cancer, at any medical facility, with tumor tissue collected at biopsy or surgery and stored for current or future testing. The study aims to learn whether researchers can return the test results to the patient and their clinicians, and whether this information provides added benefit over standard care. Exclusions include patients who decline definitive therapies, those with comorbidities that prevent definitive therapies, and patients on hospice.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer is being studied. Conditions: Advanced/Recurrent Breast Cancer, Endometrial Cancer, Ovarian Cancer • Eligibility: Inclusion Criteria: * Patients with proven advanced breast cancer, endometrial cancer or ovarian cancer, who are refractory to standard therapies or for whom no standard therapy exists. *…. Goal: A study to examine the combination of temsirolimus and Caelyx® (chemotherapeutic) in advanced or recurrent breast, endometrial and ovarian cancer. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Radboud University Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Questionnaire Study for Gynecological Cancer Survivors is being studied. Conditions: Endometrial Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms +3 • Eligibility: Inclusion Criteria: * Female participants diagnosed with gynecologic cancer * Participants between the ages of 20 and 75 years old, inclusive * Participants previously treated for all stages…. Goal: The purpose of this study is to evaluate the quality of life of long-term gynecologic cancer survivors. Phase/Status/Sponsor: Unknown phase; UNKNOWN; U.S. Army Medical Research and Development Command.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Retrospective Study to Evaluate the Feasibility of Ovarian Preservation in Patients With Endometrial Carcinoma is being studied. Conditions: Endometrial Cancer • Eligibility: Inclusion Criteria: * early stage endometrial cancer after primary surgery exclusion criteria: * MMMT, type 2 endometrial cancer. Goal: Endometrial cancer is one of the most common female malignancies in the United States, and has increased in incidence in Taiwan in recent decades.A recent population-based analysis noted that 4% of endometrial cancers occurred in women aged 40 years or younger, furthermore it is up to 15% in Taiwan according to the data of cancer registry. The standard treatment of endometrial cancer results in surgical menopause and places patients at risk for the long-term sequelae of estrogen deprivation. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Taipei Veterans General Hospital, Taiwan.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells. is being studied. Conditions: Solid Tumor, Adult • Eligibility: Inclusion Criteria: Cohort Legend: Cohort 1: On-Treatment Responder (Biopsy), Cohort 2: Pre and On-Treatment (Biopsy), Cohort 3: On-Treatment Responder (Surgery), Cohort 4: Post-Treatment Vitiligo, Cohort 5: Post-Treatment Responder…. Goal: T Cell Receptor-engineered T-cell therapy (TCR T-cell therapy) offers a potentially transformative approach to treating cancer, but is currently limited by the lack of known targets (Maus and June, 2016; Ping et al., 2018). Arguably the most clinically meaningful way to discover new targets and TCRs for TCR T-cell therapy is to study the tumor-infiltrating lymphocytes of patients that are actively responding to immune checkpoint inhibitor (ICI) therapy. Phase/Status/Sponsor: Unknown phase; UNKNOWN; TScan Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903 is being studied. Conditions: Ovarian Cancer, Cervical Cancer, Endometrial Cancer +2 • Eligibility: Inclusion Criteria: * Agreement to provide fresh or archived tumor tissue sample within 3 years * Ia (dose escalation phase and dose expansion phase):patients with pathologically confirmed advanced…. Goal: This is an open phase I/Ib clinical study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and initial efficacy of RP903 in patients with advanced malignancies who have failed standard treatment or have no standard treatment options. The study was divided into two parts: dose escalation and dose extension (Phase Ia) and clinical extension (Phase Ib). Phase/Status/Sponsor: Unknown phase; COMPLETED; Risen (Suzhou) Pharma Tech Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. is being studied. Conditions: Cervical Cancer, Endometrial Cancer, Ovarian Epithelial Cancer • Eligibility: Inclusion Criteria: * GYN cancer (ovarian, endometrial, or cervical) was biopsy-proven and/or schedule for subsequent surgery based on clinical presentation (imaging, markers) * Age ≥ 18 years. *…. Goal: An important part of staging and deciding the method of treatment is knowing areas of how cancer is involved. Diagnostic imaging is often used to determine the location of the cancer using techniques like nuclear medicine, MRI (magnetic resonance imaging), CT (computerized tomography), and ultrasound. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Bital Savir-Baruch.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in Taiwan is being studied. Conditions: Cervical Cancers, Endometrial Cancer, Ovarian Cancer • Eligibility: Inclusion Criteria: 1. Adults aged ≥ 18 years when their clinical data are reviewed 2. Patients who fulfill ONE of the following criteria * Imaging or histological diagnosis…. Goal: Trastuzumab Deruxtecan (T-DXd) is a humanized anti-HER2 monoclonal antibody covalently linked to DXd, which is a topoisomerase 1 inhibitor. T-DXd has been approved for the treatment of HER2-positive breast cancer, HER2-mutated lung cancer, HER2-positive gastric cancer, and HER2-low breast cancer in Taiwan. Phase/Status/Sponsor: Unknown phase; COMPLETED; Daiichi Sankyo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1 Study of [225Ac]-FPI-1434 Injection is being studied. Conditions: Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer +7 • Eligibility: Inclusion Criteria: 1. Pathologically documented, definitively diagnosed, advanced solid tumour that is refractory to all standard treatment, for which no standard treatment is available, or it is contraindicated,…. Goal: This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of \[225Ac\]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of \[225Ac\]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent). Phase/Status/Sponsor: Unknown phase; TERMINATED; Fusion Pharmaceuticals Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Registry of Oncology Outcomes Associated with Testing and Treatment is being studied. Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer +73 • Eligibility: Inclusion Criteria: * Patient or representative provides written informed consent * Patient is diagnosed with advanced malignancy * Patient is willing to be treated for this malignancy according…. Goal: This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Taproot Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Multiorgan Metabolic Imaging Response Assessment of Abemaciclib is being studied. Conditions: Esophageal Adenocarcinoma, Esophagus SCC, Cholangiocarcinoma +2 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years old 2. Female or male 3. ECOG performance status ≤ 1 4. Life expectancy of greater than 12 weeks 5. Must…. Goal: Open-label, phase II, basket trial. This trial is a screening program for abemaciclib efficacy in multiple platinum-resistant tumour types by using metabolic imaging (PERCIST) and RECIST v1.1 criteria. Phase/Status/Sponsor: Unknown phase; COMPLETED; Jules Bordet Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers is being studied. Conditions: Gynecologic Neoplasms, Epithelial Ovarian Cancer, Uterine Endometrial Cancer +2 • Eligibility: Inclusion Criteria: 1. Have histologically or cytologically confirmed gynecologic tumor of müllerian origin, specifically epithelial ovarian, fallopian tube, primary peritoneal, or uterine endometrial cancer. 2. Have disease amenable…. Goal: The ultimate goal of the study is to identify potential biomarkers, immune gene expression signatures, and co-stimulatory pathways that may be used to understand the effect of immune checkpoint inhibitors on gynecologic cancers. Phase/Status/Sponsor: Unknown phase; COMPLETED; AA Secord.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Benign Reproductive Tissue Analysis for Endometrial Cancer Markers is being studied. Conditions: Oophorectomy for Benign Reasons, Hysterectomy • Eligibility: * INCLUSION CRITERIA: * Inclusion criteria include: 18 years of age and older with: * a benign condition for which subject has decided to have a hysterectomy (removal…. Goal: Background: * Endometrial cancer (cancer of the lining of the uterus) is the most common gynecologic cancer in the United States. * Currently, there are no markers (components of blood and tissue that determine who might be at risk for developing cancer) for endometrial cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Motivational Interviewing to Increase Physical Activity Behaviour in Cancer Patients is being studied. Conditions: Cancer, Breast, Cancer of Colon, Endometrial Cancer • Eligibility: Inclusion Criteria: * breast, endometrial or colorectal cancer * cancer stage ≤ stage III * \> 3 months after primary treatment * \< 24 months after primary treatment…. Goal: Physical activity is not only efficient for primary prevention of several cancer types, but it also plays an important role in cancer survivors. Physical activity after a cancer diagnosis has been associated with reduced overall and cancer-specific mortality. Phase/Status/Sponsor: Unknown phase; COMPLETED; Luxembourg Institute of Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation Adherence/Toxicity in Patients With Non-Ovarian Gynecological Cancers is being studied. Conditions: Non-ovarian Gynecological Cancers • Eligibility: Inclusion Criteria: * ≥Age 18 years (no upper age limit) * Diagnosis of cervical, vaginal, vulvar, or endometrial cancer with either pelvic radiotherapy or chemoradiotherapy planned as part…. Goal: The purpose of this study is to investigate the association between the Independent Activities of Daily Living (I-ADL) component of the Comprehensive Geriatric Assessment (CGA) and poor tolerance to radiation treatment in older and younger patients with non-ovarian gynecological cancers. Phase/Status/Sponsor: Unknown phase; COMPLETED; UNC Lineberger Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sentinel Node and Endometrial Cancer is being studied. Conditions: Endometrial Neoplasms • Eligibility: Inclusion Criteria: * patient over 18 years old with a surgery planned for endometrial cancer * endometrial cancer proved by biopsy * early stage of endometrial cancer (FIGO…. Goal: The purpose of this study is to investigate the relevance of sentinel node in endometrial cancer. Sentinel node is thought to reflect the status of lymph node. Phase/Status/Sponsor: Unknown phase; COMPLETED; Assistance Publique - Hôpitaux de Paris.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma is being studied. Conditions: Endometrial Cancer, Kidney Cancer, Metastatic Cancer +3 • Eligibility: DISEASE CHARACTERISTICS: Histologically proven soft tissue sarcoma with pulmonary metastases for which radical metastasectomy is feasible Eligible subtypes: Malignant fibrous histiocytoma Liposarcoma Synovial sarcoma Malignant paraganglioma Fibrosarcoma Leiomyosarcoma…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; European Organisation for Research and Treatment of Cancer - EORTC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer is being studied. Conditions: Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer +3 • Eligibility: DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following: * Recurrent ovarian, fallopian tube, or peritoneal cavity cancer * Metastatic breast cancer * Advanced endometrial cancer * Planning…. Goal: RATIONALE: Pyridoxine (vitamin B6) may prevent or lessen hand-foot syndrome caused by chemotherapy. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome. Phase/Status/Sponsor: Unknown phase; COMPLETED; Case Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors is being studied. Conditions: Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer +9 • Eligibility: Inclusion Criteria: 1. Patients who have completed the HLA Typing and Tumor Neoantigen Identification Protocol (TCR001-002) and for whom a TCR(s) matching the subject's somatic mutation(s) and HLA…. Goal: A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors Phase/Status/Sponsor: Unknown phase; TERMINATED; Alaunos Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer is being studied. Conditions: Neoplasms • Eligibility: Inclusion Criteria: * Adult patients aged \>/=18 years, able to provide informed consent and willing to comply with all study procedures. * Histologically confirmed advanced or metastatic solid…. Goal: Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer Phase/Status/Sponsor: Unknown phase; COMPLETED; Vincerx Pharma, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab Trial in Endometrial Cancer - AtTEnd is being studied. Conditions: Endometrial Cancer • Eligibility: Inclusion Criteria: I-1. Newly diagnosed, histologically-confirmed with residual disease after surgery either measurable or evaluable, or inoperable stage III-IV endometrial carcinoma/carcinosarcoma, after diagnostic biopsy, and naïve to first…. Goal: Atezolizumab is an engineered humanised monoclonal immunoglobulin G1 antibody that binds selectively to PD-L1 and prevents its interaction with PD-1 and B7-1. In May 2016 atezolizumab was approved by the FDA for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following any platinum-containing chemotherapy, or within 12 months of receiving chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant); in October 2016 it was approved by the FDA for patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities. Phase/Status/Sponsor: Unknown phase; COMPLETED; Mario Negri Institute for Pharmacological Research.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a screening study in which no therapy is given, to see if a patient’s tumor mutations and HLA type match Alaunos Therapeutics’ TCR library for potential autologous TCR-T cell therapy in a Phase I/II program. It targets adults with certain advanced cancers (gynecologic ovarian/endometrial, colorectal, pancreatic, non-small cell lung cancer, or cholangiocarcinoma) who have progressed after at least one prior treatment. The study tests somatic mutations and high‑resolution HLA typing to determine if a matching TCR is available; if a match is found, the patient may enroll in the Phase I/II therapy; if not, they are discontinued from this protocol. Exclusions include unstable medical conditions, primary immunodeficiency, active cancers requiring treatment (with limited exceptions), bleeding disorders or chronic anticoagulation, recent organ transplant, or xenotransplantation, and participants must have prior genomic testing or plan biopsy and provide informed consent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors is being studied. Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor +2 • Eligibility: Inclusion Criteria: * Signed informed consent * Subjects must be ≥ 18 years of age ( ≥ 20 years of age for Taiwan site) * Subject with advanced…. Goal: ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors. The ACE1702-001 phase I study aims to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing tumors, and to determine the phase Ib/II starting dose for ACE1702. Phase/Status/Sponsor: Unknown phase; COMPLETED; Acepodia Biotech, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) is being studied. Conditions: Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma +13 • Eligibility: Inclusion Criteria: 1. Subjects in Part A (dose escalation) must have a diagnosis of any of the following: Histologically or cytologically confirmed advanced solid tumors, including the following:…. Goal: This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Xencor, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795 is being studied. Conditions: Cancer • Eligibility: Inclusion Criteria: * Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. * Male or female, 18 years…. Goal: This study is a first time in human, Phase I, open-label, dose-escalation study of the oral AKT inhibitor GSK2141795 in subjects with solid tumors or lymphomas. Phase/Status/Sponsor: Unknown phase; COMPLETED; GlaxoSmithKline.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema is being studied. Conditions: Ovarian Cancer, Uterine Cancer, Vaginal Cancer +1 • Eligibility: Inclusion Criteria: * Study group of Gynecologic cancer survivors with Lymphedema * Documented lower extremity lymphedema * History of a primary diagnosis of gynecologic cancer (vulvar, cervical and…. Goal: The purpose of this study is to evaluate if the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) truly detects symptoms or signs of lower extremity lymphedema in patients with diagnosed lower extremity lymphedema. Lymphedema is a chronic condition in which fluid accumulates in the tissues of the body. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Extended Follow-up of Columbia, MO Serum Bank Participants is being studied. Conditions: Breast Cancer, Endometrial Cancer, Ovarian Cancer • Eligibility: * Not listed.. Goal: The Columbia, MO Serum Bank initially was established in 1977 as part of the National Cancer Institute's (NCI) Biological Markers Project to identify serum markers for breast cancer. Participants were volunteers identified through the Breast Cancer Detection Demonstration Project (BCDDP) at the University of Missouri Hospital and Ellis Fischel Cancer Center in Columbia, MO. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors is being studied. Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer +14 • Eligibility: Inclusion Criteria: To be eligible for participation in the study, patients must meet the following inclusion criteria: * Locally-advanced or metastatic solid tumor with an NRG1 gene fusion…. Goal: This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion. Phase/Status/Sponsor: Unknown phase; TERMINATED; Elevation Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer is being studied. Conditions: Gynecologic Cancer, Cervical Cancer, Endometrial Cancer +2 • Eligibility: Inclusion Criteria: * Histologically confirmed primary cancer of the uterine cervix, uterine corpus, ovary, and fallopian tube * FIGO stage Cervical cancer: FIOG stage IA2-IIA2 Uterine cancer: FIGO…. Goal: To compare the incidence of lymphocele and lymphatic ascites between patient who use versus who do not use FloSeal during lymph node dissection Phase/Status/Sponsor: Unknown phase; COMPLETED; Asan Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes is being studied. Conditions: Solid Tumor • Eligibility: Key Inclusion Criteria: * Unresectable, locally advanced or metastatic solid tumor and relapsed/progressive disease * Measurable disease per RECIST v1.1 or modified RECIST v1.1 and PCWG3 (for prostate…. Goal: A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes. Phase/Status/Sponsor: Unknown phase; TERMINATED; pharmaand GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Endometrial Cancer and Fractalkine-receptor Axis of Fractalkine is being studied. Conditions: Endometrial Cancer • Eligibility: Inclusion Criteria: * Patients suffering from endometrial hypertrophy or endometrial cancer Exclusion Criteria: * no. Goal: The endometrial cancers are among the most common malignancies in postmenopausal women with an incidence on the rise. It is most often a endometrioid adenocarcinoma (grade I, II, III). Phase/Status/Sponsor: Unknown phase; COMPLETED; Centre Hospitalier Universitaire de Nice.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study anonymously screens archived tissue samples from Ashkenazi Jewish individuals with cancer to test for three common BRCA founder mutations (in BRCA1/BRCA2). - Participants are people who self-identify as Jewish and have cancer, with a tumor block or DNA available for testing at MSKCC or collaborating centers. - The goal is to find out how common these mutations are in this group and whether carriers may have a higher risk of cancers beyond breast and ovarian cancer. - Researchers will analyze results by cancer type and use the findings to identify people who might benefit from genetic counseling or testing and to inform high-risk screening or preventive options.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer is being studied. Conditions: Ovarian Cancer, Endometrial Cancer, Recurrent Ovarian Cancer +1 • Eligibility: Inclusion Criteria: * Age ≥ 18 years with a recurrent solid tumor in the Phase I portion of the trial or in the Phase II portion of the…. Goal: The purpose of the first part of this study or the dose escalation portion of the study is to determine what dose of BKM120 and Abraxane is safe to give when the two drugs are used at the same time in patients who are diagnosed with a solid cancer. A solid cancer is a cancer that does not involve the blood, bone marrow or lymph nodes. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; Rutgers, The State University of New Jersey.

This summary may be inaccurate. Verify against ClinicalTrials.gov.